NAVB
(NYSE)
0.7953
+0.0157  (+1.97%)
Volume (24h): 24,685.00 Day Range: 0.7800 - 0.8000
Market Cap: 16.26M 52W Range: 0.1250 - 2.91
Mar-31-20 11:30AM Navidea Biopharmaceuticals Signs Letter of Intent with WorldCare Clinical to Partner on Navidea’s Rheumatoid Arthritis Clinical Imaging Workflow and Commercialization; Other Business UpdatesBusiness Wire
Mar-24-20 08:19PM Edited Transcript of NAVB earnings conference call or presentation 11-Mar-20 9:00pm GMTThomson Reuters StreetEvents
02:37PM Edited Transcript of NAVB earnings conference call or presentation 11-Mar-20 9:00pm GMTThomson Reuters StreetEvents
Mar-23-20 08:10AM Edited Transcript of NAVB earnings conference call or presentation 11-Mar-20 9:00pm GMTThomson Reuters StreetEvents
02:48AM Edited Transcript of NAVB earnings conference call or presentation 11-Mar-20 9:00pm GMTThomson Reuters StreetEvents
Mar-20-20 11:00AM Navidea Biopharmaceuticals Announces Issuance of Patent Extension for Lymphoseek®Business Wire
Mar-12-20 07:00AM Edited Transcript of NAVB earnings conference call or presentation 11-Mar-20 9:00pm GMTThomson Reuters StreetEvents
Mar-11-20 08:05PM Navidea Biopharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial ResultsBusiness Wire
07:00PM Navidea Biopharmaceuticals, Inc. to Host Earnings CallACCESSWIRE
Mar-04-20 01:00PM Navidea Biopharmaceuticals to Host Fourth Quarter 2019 Earnings Conference Call and Corporate UpdateBusiness Wire
Feb-21-20 01:42PM Insider Buying: John Scott Just Spent US$2.0m On Navidea Biopharmaceuticals, Inc. (NYSEMKT:NAVB) SharesSimply Wall St.
Feb-14-20 04:56PM Navidea Biopharmaceuticals Regains Compliance with NYSE American Continued Listing StandardsBusiness Wire
12:28PM Navidea Biopharmaceuticals Announces $4.2 Million Sale of Ohio Court Judgment and $3.4 Million Equity Raise Representing $7.6 Million in Additional FundingBusiness Wire
Feb-12-20 02:20PM Investors Who Bought Navidea Biopharmaceuticals (NYSEMKT:NAVB) Shares Five Years Ago Are Now Down 97%Simply Wall St.
Dec-30-19 10:19PM Navidea Biopharmaceuticals Obtains Partial Dismissal of Claims in New YorkBusiness Wire
Dec-14-19 02:41PM The of Navidea Biopharmaceuticals, Inc. (NYSEMKT:NAVB), John Scott, Just Bought 11% More SharesSimply Wall St.
Dec-06-19 11:23PM Navidea Biopharmaceuticals Announces $1.9 Million Private PlacementBusiness Wire
Dec-05-19 08:45PM Navidea Biopharmaceuticals to Present at the 12th Annual LD Micro Main EventBusiness Wire
Dec-02-19 07:08PM Navidea Biopharmaceuticals Wins Summary Judgment in OhioBusiness Wire
Nov-20-19 03:41AM Edited Transcript of NAVB earnings conference call or presentation 7-Nov-19 10:00pm GMTThomson Reuters StreetEvents
Nov-19-19 11:22PM Edited Transcript of NAVB earnings conference call or presentation 7-Nov-19 10:00pm GMTThomson Reuters StreetEvents
Nov-16-19 09:40PM Edited Transcript of NAVB earnings conference call or presentation 7-Nov-19 10:00pm GMTThomson Reuters StreetEvents
04:52PM Edited Transcript of NAVB earnings conference call or presentation 7-Nov-19 10:00pm GMTThomson Reuters StreetEvents
Nov-14-19 01:30PM Navidea Biopharmaceuticals to Present at the PCG Spotlight Series ConferenceBusiness Wire
Nov-13-19 12:38PM What Kind Of Shareholders Own Navidea Biopharmaceuticals, Inc. (NYSEMKT:NAVB)?Simply Wall St.
Nov-08-19 09:03PM Edited Transcript of NAVB earnings conference call or presentation 7-Nov-19 10:00pm GMTThomson Reuters StreetEvents
Nov-07-19 09:05PM Navidea Biopharmaceuticals Reports Third Quarter 2019 Financial ResultsBusiness Wire
12:30PM Navidea Biopharmaceuticals Announces Preclinical Therapeutic Research Collaboration with IMV Inc. to Explore the Potential Combinatory Effect with Their Platform-Based ImmunotherapiesBusiness Wire
Oct-31-19 11:30AM Navidea Biopharmaceuticals to Host Third Quarter 2019 Earnings Conference Call and Corporate UpdateBusiness Wire
Oct-29-19 11:30AM Navidea Biopharmaceuticals Announces Positive Results of First Interim Analysis of Ongoing Phase 2B Study in Rheumatoid ArthritisBusiness Wire
Oct-14-19 07:42PM Edited Transcript of NAVB earnings conference call or presentation 8-Aug-19 9:00pm GMTThomson Reuters StreetEvents
Sep-06-19 08:05PM Navidea Biopharmaceuticals to Present at the H.C. Wainwright 21st Annual Global Investment ConferenceBusiness Wire
Aug-27-19 11:30AM Navidea Biopharmaceuticals Announces Receipt of Notice of AwardBusiness Wire
Aug-15-19 12:38AM Edited Transcript of NAVB earnings conference call or presentation 8-Aug-19 9:00pm GMTThomson Reuters StreetEvents
Aug-08-19 08:05PM Navidea Biopharmaceuticals Reports Second Quarter 2019 Financial ResultsBusiness Wire
Aug-01-19 08:05PM Navidea Biopharmaceuticals Schedules Second Quarter 2019 Earnings Conference Call and Business UpdateBusiness Wire
Jun-24-19 11:46AM Navidea Biopharmaceuticals Announces SNMMI Press Release and Recognition of Phase 1/2 Study ResultsBusiness Wire
Jun-18-19 08:05PM Navidea Biopharmaceuticals Announces Closing of Public Offering of Common StockBusiness Wire
05:30PM Edited Transcript of NAVB earnings conference call or presentation 8-May-19 9:00pm GMTThomson Reuters StreetEvents
Jun-17-19 09:16PM Navidea Biopharmaceuticals Announces Day and Time of SNMMI Presentation of Phase 1/2 Study Results and Enrollment Update on its Phase 2B StudyBusiness Wire
Jun-14-19 03:16AM Navidea Biopharmaceuticals Prices $6.0 Million Public Offering of Common StockBusiness Wire
Jun-13-19 09:31PM Navidea Biopharmaceuticals Announces Proposed Public Offering of Common StockBusiness Wire
08:24PM Navidea Biopharmaceuticals Regains Direct Control of Intellectual PropertyBusiness Wire
May-08-19 10:28PM Navidea: 1Q Earnings SnapshotAssociated Press
Navidea Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. The company operates in two segments, Diagnostic Substances and Therapeutic Development Programs. The company develops Manocept platform to target the CD206 mannose receptor expressed on activated macrophages; and NAV4694, a fluorine-18 labeled positron emission tomography imaging agent for use as an aid in the imaging and evaluation of patients with signs or symptoms of Alzheimers disease and mild cognitive impairment. It is also developing NAV5001, an iodine-123 labeled single photon emission computed tomography imaging agent that is used as an aid in the diagnosis of Parkinson's disease and other movement disorders with potential use as a diagnostic aid in dementia; diagnostic substances, including technetium 99m tilmanocept and other diagnostic applications of its Manocept platform; and therapeutic development programs, such as therapeutic applications of its Manocept platform, as well as various development programs. The company was formerly known as Neoprobe Corporation and changed its name to Navidea Biopharmaceuticals, Inc. in January 2012. Navidea Biopharmaceuticals, Inc. was founded in 1983 and is headquartered in Dublin, Ohio.
Stocks in other countries: United Kingdom India Canada Australia
Market Cap
Volume (24h)